Top 50 Health Care VC Funds & Investors in Asia (October 2026)
For AI agents: Short investor table (Markdown), Detailed investor list (Markdown)
| Investor | Relevant Deals | Geography | Stage | Focus | Round Size |
|---|---|---|---|---|---|
|
Qiming Venture Partners
VC Fund
|
153 | China, United States, Hong Kong | Series B, Series A, Series C | Health Care, Biotechnology, Medical | $4.3M–$120M |
|
HSG
VC Fund
|
87 | China, United States, Singapore | Series A, Series B, Seed | Artificial Intelligence, Software, Health Care | $2M–$200M |
|
BioVenture
VC Fund
|
78 | China, United States, Hong Kong | Series A, Series B, Seed | Health Care, Biotechnology, Medical | $4.4M–$85M |
|
Antler
VC Fund
|
68 | United States, Singapore, Australia | Pre-Seed, Seed, Series A | Software, Artificial Intelligence, Information Technology | $100k–$29M |
|
Matrix Partners China
VC Fund
|
67 | China, United States, Singapore | Series A, Series B, Seed | Health Care, Software, Biotechnology | $1.2M–$137M |
|
IDG Capital
VC Fund
|
59 | China, United States, Singapore | Series A, Series B, Seed | Internet, Software, E-Commerce | $600k–$110M |
|
Mitsubishi UFJ Capital
VC Fund
|
57 | Japan, United States, Israel | Series A, Venture - Series Unknown, Seed | Software, Information Technology, Manufacturing | $470k–$21M |
|
Lilly Asia Ventures
VC Fund
|
55 | China, United States, Hong Kong | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $14M–$308M |
|
Med-Fine Capital
VC Fund
|
52 | China, Hong Kong, United States | Series A, Seed, Series B | Medical, Health Care, Biotechnology | $3M–$60M |
|
Legend Capital
VC Fund
|
50 | China, United States, South Korea | Series B, Series A, Series C | Health Care, Medical, Biotechnology | $2.9M–$200M |
|
ANRI
VC Fund
|
49 | Japan, United States, Indonesia | Seed, Series A, Venture - Series Unknown | Software, Health Care, Information Technology | $268k–$41M |
|
Frees Fund
VC Fund
|
48 | China, United States, Singapore | Series A, Seed, Angel | Artificial Intelligence, Health Care, Biotechnology | $447k–$28M |
|
Shenzhen Capital Group
VC Fund
|
47 | China, United States, Japan | Series A, Series B, Seed | Manufacturing, Health Care, Software | $1.4M–$141M |
|
ZhenFund
VC Fund
|
47 | China, United States, Singapore | Seed, Series A, Angel | Artificial Intelligence, Software, E-Commerce | $146k–$22M |
|
Northern Light Venture Capital
VC Fund
|
44 | China, United States, South Korea | Series A, Series B, Venture - Series Unknown | Health Care, Medical, Biotechnology | $1.5M–$60M |
|
East Ventures
VC Fund
|
43 | Japan, Indonesia, Singapore | Seed, Series A, Venture - Series Unknown | Software, Information Technology, E-Commerce | $250k–$30M |
|
Highlight Capital
VC Fund
|
41 | China, United States, South Korea | Series A, Series B, Seed | Health Care, Medical, Biotechnology | $3.1M–$84M |
|
SMBC Venture Capital
VC Fund
|
41 | Japan, United States, Singapore | Venture - Series Unknown, Series A, Series B | Information Technology, Software, Health Care | $800k–$34M |
|
Seeds Capital
VC Fund
|
38 | Singapore, United States, Hong Kong | Seed, Series A, Series B | Biotechnology, Artificial Intelligence, Health Care | $767k–$45M |
|
Puhua Capital
VC Fund
|
38 | China, United Kingdom, United States | Series A, Series B, Seed | Manufacturing, Health Care, Medical | $1.5M–$103M |
|
Kaitai Capital
VC Fund
|
38 | China, United States, Singapore | Series A, Seed, Series B | Biotechnology, Health Care, Pharmaceutical | $1.4M–$57M |
|
Cowin Capital
VC Fund
|
38 | China, United States, Hong Kong | Series A, Series B, Seed | Manufacturing, Health Care, Semiconductor | $1.4M–$51M |
|
Fast Track Initiative, Inc.
VC Fund
|
37 | Japan, United States, United Kingdom | Series A, Series B, Seed | Health Care, Biotechnology, Medical | $345k–$117M |
|
Legend Star
VC Fund
|
35 | China, United States, France | Series A, Seed, Angel | Health Care, Medical, Robotics | $425k–$52M |
|
BioTrack Capital
VC Fund
|
35 | China, United States, Singapore | Series A, Series B, Seed | Biotechnology, Health Care, Medical | $14M–$168M |
|
UntroD Capital
VC Fund
|
34 | Japan, Singapore, Austria | Seed, Venture - Series Unknown, Series A | Manufacturing, Biotechnology, Health Care | $316k–$15M |
|
Dalton Venture
VC Fund
|
33 | China, India, Canada | Seed, Series A, Series B | Health Care, Medical, Biotechnology | $512k–$50M |
|
Lenovo Capital and Incubator Group (LCIG)
VC Fund
|
33 | China, Hong Kong, United States | Series A, Seed, Series B | Manufacturing, Artificial Intelligence, Software | $1.4M–$150M |
|
Nissay Capital
VC Fund
|
33 | Japan, United States, Ethiopia | Venture - Series Unknown, Seed, Series A | Health Care, Software, Medical | $455k–$12M |
|
Marathon Venture Partners
VC Fund
|
31 | China, United States, Hong Kong | Series A, Series B, Seed | Health Care, Medical, Biotechnology | $1.5M–$142M |
|
Shanghai Biomedical Industrial Equity Investment Fund
VC Fund
|
31 | China, United States, Hong Kong | Series A, Seed, Series B | Health Care, Medical, Biotechnology | $8M–$159M |
|
CDH Investments
VC Fund
|
31 | China, United States, Canada | Series A, Series B, Series C | Manufacturing, Health Care, Biotechnology | $3M–$220M |
|
JAFCO
VC Fund
|
30 | Japan, United States, India | Series A, Series B, Venture - Series Unknown | Information Technology, Software, Artificial Intelligence | $1.4M–$41M |
|
Taiyu Investment
VC Fund
|
29 | China | Seed, Series A, Angel | Medical, Health Care, Biotechnology | $434k–$100M |
|
Longpan Investment
VC Fund
|
29 | China, United States, Cayman Islands | Series A, Seed, Series B | Health Care, Medical, Biotechnology | $14M–$60M |
|
UTEC - The University of Tokyo Edge Capital Partners
VC Fund
|
29 | Japan, United States, India | Seed, Series A, Series B | Health Care, Biotechnology, Medical | $624k–$20M |
|
CD Capital
VC Fund
|
29 | China, United States | Series A, Series B, Seed | Health Care, Biotechnology, Medical Device | $1.4M–$34M |
|
Cowin Venture
VC Fund
|
29 | China, United States, Hong Kong | Series A, Angel, Series B | Health Care, Biotechnology, Medical | $52k–$257M |
|
Prox Ventures
VC Fund
|
28 | China, United States, United Kingdom | Seed, Series A | Medical, Biotechnology, Health Care | $2.5M–$30M |
|
Sinovation Ventures
VC Fund
|
28 | China, United States, Hong Kong | Series A, Seed, Series B | Software, Artificial Intelligence, Health Care | $882k–$74M |
|
Sherpa Healthcare Partners
VC Fund
|
28 | China, United States, Kenya | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $7.2M–$128M |
|
Addor Capital
VC Fund
|
27 | China, Hong Kong, United States | Series A, Series B, Venture - Series Unknown | Manufacturing, Semiconductor, Electronics | $1.4M–$145M |
|
Huagai Capital
VC Fund
|
27 | China, United States, Hong Kong | Series A, Series B, Angel | Health Care, Medical, Biotechnology | $425k–$90M |
|
Green Pine Capital Partners
VC Fund
|
26 | China, United States, Canada | Series A, Angel, Series B | Artificial Intelligence, Biotechnology, Manufacturing | $425k–$150M |
|
Mizuho Capital
VC Fund
|
26 | Japan, United States, Singapore | Series A, Venture - Series Unknown, Series B | Information Technology, Software, Artificial Intelligence | $661k–$47M |
|
Hillhouse Investment
VC Fund
|
26 | China, United States, Singapore | Series B, Series A, Series C | Biotechnology, Health Care, Medical | $2.9M–$300M |
|
Gaorong Capital
VC Fund
|
26 | China, United States, Singapore | Series A, Series B, Seed | Artificial Intelligence, Information Technology, Software | $1.6M–$110M |
|
Oriza Holdings
VC Fund
|
25 | China, United States, Canada | Series A, Series B, Series C | Manufacturing, Health Care, Biotechnology | $1.5M–$200M |
|
Shunwei Capital
VC Fund
|
25 | China, United States, India | Series A, Series B, Seed | Manufacturing, Software, Artificial Intelligence | $1M–$74M |
|
Nippon Venture Capital
VC Fund
|
25 | Japan, United States, Indonesia | Venture - Series Unknown, Series A, Series B | Software, Health Care, Medical | $457k–$45M |
| Access all 50 VC funds in Asia Health Care startups. | |||||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Investor list
Founded in 2006, Qiming Venture Partners is a leading China venture capital firm with offices in Shanghai, Beijing, Suzhou, Hong Kong in China, and Singapore.Currently, Qiming Venture Partners manages eleven US Dollar funds and seven RMB funds with $9.5 billion in capital raised. Since our establishment, we have invested in outstanding companiesin the Technology and Consumer (T&C) and Healthcare industries at the early and growth stages.Since our debut, we have backed over 530 fast-growing and innovative companies. Over 200 of our portfolio companies have achieved exits through IPOs at the NYSE, NASDAQ, HKEX, Shanghai Stock Exchange, or Shenzhen Stock Exchange, or through M&A or other means. There are also over 70 portfolio companies that have achieved unicorn or super unicorn status.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Series B, Series A, Series C
- Geography: China, United States, Hong Kong
Investor stats
- Total investments: 1195
- Round size: Series A $4.3M–$48M; Series B $7.9M–$90M; Series C $12M–$120M
- Lead/follow: 51% lead, 49% follow
- Last fund: Likely actively investing — fresh fund, raised $8M in 2026
Portfolio highlights
- LP Amina — LP Amina focuses on products that improve coal-fired power plant's emissions and efficiency. Leveraging 50 unique patented products to improve the firing system of a coal-fired boiler, including Rotating Vane Wheels, High Performance Classifiers, Coal Pipe Balancing Technologies, and Burner Enhancements, the Company provides products andsolutions that will meet or exceed the expectations of their customers. Furthermore, LP Amina's corporate culture is one of a relentless pursuit of continuous improvement. Utilizing the latest technology and traditional know-how from the World's two largest users of Coal for power generation, the Company is well positioned to develop new products and solutions to meet the ever changing needs of Power Industry.LP Amina's staff has over 20 years of experience in the design, fabrication, installation and commissioning of coal-fired power plants. During this time, the team has gained a wide range of experience from the evolution of the US Power Market. Increases in environmental regulations and free market driven energy prices have forced plant operators to reduce emissions and improve reliability while lowering operational cost. LP Amina's engineering and design team will leverage this experience gained from the US and Europe to address the emergence of similar issues in China.
- Nice Tuan — Nice Tuan is an e-commerce platform that provides daily groceries and miscellaneous products.
- Shennapsi Artificial Intelligence Technology — Synapsor is a medical-grade wearable device research and development company, oriented to the AI+ medical and health field, and is committed to the development and manufacturing of AI-powered medical-grade smart wearable devices, including AI-ECG artificial intelligence. Diagnostic analysis system, CUMS uric acid blood glucose and cholesterolmonitoring system, etc. The company has recently received tens of millions of yuan in Series B investment, and the investor is Xiaomi Technology.
HSG is a leading venture capital and private equity firm investing globally in the technology, healthcare, and consumer sectors.
Show more...Investment focus
- Industry: Artificial Intelligence, Software, Health Care
- Stage:Series A, Series B, Seed
- Geography: China, United States, Singapore
Investor stats
- Total investments: 1085
- Round size: Seed $2M–$50M; Series A $4M–$100M; Series B $11M–$200M
- Lead/follow: 45% lead, 55% follow
- Last fund: Likely still investing — raised $2.5B in 2024
Portfolio highlights
- Z.ai — The AI Lab behind GLM models, dedicated to inspiring the development of AGI to benefit humanity. https://t.co/gOw7WpwkJt https://t.co/ot9sGVXU8x
- BCI-Sonics — BCI-Sonics is an innovative medtech company developing non-invasive brain-computer interface solutions using advanced transcranial focused ultrasound (tFUS) technology. The company builds a next-generation therapeutic platform enabling precise neuromodulation to treat central nervous system disorders. BCI-Sonics develops low-intensity focusedultrasound technology that non-invasively stimulates deep brain regions with high precision. They combine ultrasound engineering and neuroscience to interface safely and effectively with the human brain without surgery. The company is creating an AI ultrasound brain-computer interface platform for therapeutic neuromodulation applications.
- Suisheng Technology — Suisheng Technology is an innovative company specializing in AI-driven memory services, dedicated to developing intelligent solutions that help individuals and businesses capture, organize, and retrieve important information with greater efficiency and precision.
Suzhou Industrial Park Bioventure Investment Management Limited (Bioventure) was established in September 2013. Bioventure its first element of the new bio-industry funds 540 million yuan fund size. Bioventure specialize in the field of life sciences in the early stages of the venture capital investments as having high strength and growth, greaterdevelopment space, excellent management team, biotechnology, drug discovery, medical devices and healthcare services companies, and provide capital, management , operation and other aspects of post-investment support and services.Bioventure brought together senior investment professionals team with bio-pharmaceutical industry investment experience, strong fund management, entrepreneurship and venture capital and operating experience in business, have a deep understanding of the domestic and foreign markets, capable of its forward-looking international perspective and extensive The industry has the potential resources to help innovative companies grow rapidly and gain greater success, while giving fund investors bring considerable returns.Suzhou Industrial Park, the core investor BioBay has the country's best medical and pharmaceutical incubator function, use the platform, the project team has great resources and industrial service advantages, Yuan-sheng venture has successfully invested in 20 projects have been cast projects in their own development and follow-up financing, has made outstanding achievements in the industry for all to see, and won the Venture's trust and praise.By focusing and extensive industry resources, Bioventure determined to become one of China's most successful medical and pharmaceutical venture fund. Bioventure expectations and in the medical and pharmaceutical industry where there joint venture development cooperation.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Series A, Series B, Seed
- Geography: China, United States, Hong Kong
Investor stats
- Total investments: 192
- Round size: Seed $7.9M–$41M; Series A $4.4M–$47M; Series B $7.1M–$85M
- Lead/follow: 33% lead, 67% follow
- Last fund: May invest from a new fund soon — raised $204M in 2016
Portfolio highlights
- Inno Medicine — Inno Pharmaceutical Technology specializes in research on the pathogenesis of atherosclerosis. The company focuses on the development of targeted nanoliposomes, targeting molecules with independent intellectual property rights, and currently focuses on the plaque reversal treatment of atherosclerosis.
- Zhiran Medical — Zhiran Medical is a medical technology company specializing in the precise detection and treatment of neurological disorders using high-throughput, flexible brain-computer interface technology.
- MyoGene Life Sciences — MyoGene Life Sciences is a regenerative medical company that specializes in the promotion of its regenerative repair material product line for bone repair.
Build your next company with Antler, a global day zero investor enabling exceptional founders to start great companies, from the very beginning. Apply now!
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Information Technology
- Stage:Pre-Seed, Seed, Series A
- Geography: United States, Singapore, Australia
Investor stats
- Total investments: 2382
- Round size: Seed $158k–$4.6M; Pre-Seed $100k–$600k; Series A $4.1M–$29M
- Lead/follow: 43% lead, 57% follow
- Last fund: Likely actively investing — fresh fund, raised $7.5M in 2026
Portfolio highlights
- Obud — Obud is a wellness reservation systems that is designed for holistic health and lifestyle management purposes. The company's systems offer a comprehensive suite of tools for booking wellness activities, managing schedules, and accessing curated wellness programs, enabling wellness centers to streamline their operations, enhance userengagement, and promote a balanced and healthy lifestyle.
- myluigi.ai — Luigi is an AI-Powered Full-Stack Game Growth-as-a-Service platform designed to help mobile game studios scale user acquisition, engagement and lifetime value without adding headcount. Its dual-engine architecture automates and operates everything from ad campaign creation and real-time creative optimization to personalized in-game offers and LTVforecasting—delivered through a single, easy-to-integrate and unified dashboard. With a flexible per-title pricing model and powerful machine-learning insights, Luigi empowers mid-sized and indie developers to reduce CPI, boost retention and chart a clear path toward sustainable growth and seven-figure ARR.
- RubiLabs — RubiLabs Inc provides a platform for unifying, monitoring, and analyzing organizational data. RubiLabs software enables analysts and operators across risk, compliance, and security teams to collaborate and interpret large volumes of information in real time. The company’s platform is designed to help institutions make sense of complex, fragmenteddata by transforming it into a coherent operational picture for risk detection, continuous monitoring, and investigative workflows.
Matrix Partners China builds long-term relationships with entrepreneurs and helps them build significant, industry-leading companies.Since its inception in 1977, Matrix Partners China has made hundreds of investments and played an active role in the development of many successful businesses, 50 of which went on to IPO, and 75 of which have goneon to profitable M&A events. The firm consistently ranks in the top venture firms in terms of returns to its investors.Matrix Partners China combines local knowledge with global experience and vision. Its team consists of both former entrepreneurs and experienced investors. Its past successes include Focus Media, Eachnet, and Baidu, among others. The company invests across multiple sectors and stages.
Show more...Investment focus
- Industry: Health Care, Software, Biotechnology
- Stage:Series A, Series B, Seed
- Geography: China, United States, Singapore
Investor stats
- Total investments: 706
- Round size: Seed $1.2M–$74M; Series A $2.9M–$52M; Series B $10M–$137M
- Lead/follow: 37% lead, 63% follow
- Last fund: Likely still investing — raised $92M in 2023
Portfolio highlights
- Camera360 — Camera360 is a professional but easy-to use App for photo editing and selfie retouching. Tag #camera360
- BCI-Sonics — BCI-Sonics is an innovative medtech company developing non-invasive brain-computer interface solutions using advanced transcranial focused ultrasound (tFUS) technology. The company builds a next-generation therapeutic platform enabling precise neuromodulation to treat central nervous system disorders. BCI-Sonics develops low-intensity focusedultrasound technology that non-invasively stimulates deep brain regions with high precision. They combine ultrasound engineering and neuroscience to interface safely and effectively with the human brain without surgery. The company is creating an AI ultrasound brain-computer interface platform for therapeutic neuromodulation applications.
- Liepin — Liepin is the largest and most professional high-end talent community-based recruitment site, with its innovative products and unique service model model for create an interactive high-end talent recruitment platform between business, headhunting and workplace. Tens of thousands of professional executive search consultant for businesses and jobseekers set up communication between the bridge and accelerate corporate recruitment process, recommended paying jobs in the workplace, career development planning. 16 job seekers to avoid the risk of privacy protection, millions of high-end elite member libraries, help enterprises development needs.
IDG Capital is a global investment firm partnering with founders to build enduring businesses through capital, expertise, and long-term support.
Show more...Investment focus
- Industry: Internet, Software, E-Commerce
- Stage:Series A, Series B, Seed
- Geography: China, United States, Singapore
Investor stats
- Total investments: 1220
- Round size: Seed $600k–$44M; Series A $2M–$100M; Series B $6.2M–$110M
- Lead/follow: 38% lead, 62% follow
- Last fund: May invest from a new fund soon — last raise in 2017
Portfolio highlights
- Naive.ai — Naive.ai is a startup specializing in training AI agents with open-source models. It emphasizes post-training of open-source models to develop advanced AI agents.
- Arrow Yuan Technology — Arrow Yuan Technology focuses on the research and development of reusable stainless steel propellant tanks.
- Apex Intelligence — Apex Intelligence develops self-evolving AI models for scientific discovery.
Mitsubishi UFJ Capital is a venture capital firm focusing on life science, ICT, and high technology investments.
Show more...Investment focus
- Industry: Software, Information Technology, Manufacturing
- Stage:Series A, Venture - Series Unknown, Seed
- Geography: Japan, United States, Israel
Investor stats
- Total investments: 685
- Round size: Seed $470k–$16M; Series A $1.2M–$21M; Venture - Series Unknown $525k–$11M
- Lead/follow: 10% lead, 90% follow
- Last fund: May invest from a new fund soon — raised $94M in 2020
Portfolio highlights
- Caguuu — Caguuu offers high-quality designer furniture at affordable prices, through e-commerce, eliminating middlemen and store operating costs.
- Smart Craft —
- Link Therapeutics — Link Therapeutics specializes in developing therapeutic methods for targeting autoantibodies and identifying pathogenic autoantibodies.
Lilly Asia Ventures (LAV) is a leading biomedical venture capital firm headquartered in China, with offices in Shanghai, Hong Kong, and Palo Alto.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: China, United States, Hong Kong
Investor stats
- Total investments: 253
- Round size: Series A $14M–$100M; Series B $25M–$110M; Series C $30M–$308M
- Lead/follow: 27% lead, 73% follow
- Last fund: May invest from a new fund soon — raised $40M in 2019
Portfolio highlights
- InventisBio — InventisBio is a biotech company whose product pipeline includes small molecule drug candidates for targeted therapies in lung cancer, breast cancer and gout. The company is also actively developing drugs that can be combined with other immune-oncology targeted therapies, such as PD-1 antibody, for various cancer indications. The company isco-founded by Dr. Yaolin Wang and other scientists who have previously worked at Merck and Schering-Plough, leading various drug discovery projects in oncology, metabolic and infectious disease areas.
- NeuShen Therapeutics — We are a global biotech company committed to developing new and effective therapies for psychiatric and neurological disorders affecting millions of patients in need.
- Connexus Therapeutics — Connexus Therapeutics is a private, venture-backed biotechnology startup.
Med-Fine Capital is a venture capital firm focusing on early stage investments in China healthcare industry. The company is headquartered in Shanghai with offices in Beijing and Shenzhen.
Show more...Investment focus
- Industry: Medical, Health Care, Biotechnology
- Stage:Series A, Seed, Series B
- Geography: China, Hong Kong, United States
Investor stats
- Total investments: 83
- Round size: Seed $8M–$60M; Series A $3M–$40M; Series B $12M–$60M
- Lead/follow: 31% lead, 69% follow
- Last fund: May invest from a new fund soon — raised $73M in 2019
Portfolio highlights
- Zhuanma Biotech — Zhuanma Biotechnology is a gene editing service provider dedicated to clinically developing effective ultra-small gene editors into genetic therapeutics that are "curable once and for all."
- Tianyikang Biotechnology — Tianyikang Biotechnology focuses on medical research and the development and application of next-generation cell immunotherapy products.
- Beijing Ansong Technology — Beijing Ansong Technology Co., Ltd. is an enterprise focusing on the research and development, production, and sales of orthopedic medical devices. The company cooperates with domestic and foreign universities, research institutes, and doctors in hospitals, and is committed to creating original orthopedic products with independent knowledgeproducts.Beijing Ansong Technology was founded on June 27, 2011 by Liang Tao in Fengtai, Beijing.
Legend Capital, a subsidiary of Legend Holdings Ltd., started its vintage year in April, 2001 with a mission to become a top-notch and the most respected venture capital investment manager in China.Managing up to US$700 million across four funds, Legend Capital focuses on driving high-growth ventures with operations substantially based in Chinaor on markets related to China.Legend Capital mainly invests in early stage IT companies, specifically, in sectors of network applications and services, outsourcing and professional services, Infrastructure (IC design/key components), and mid-market growth stage companies in the fields of consumer goods, clean technology, health care, equipment manufacturing and modern services.Among over 60 portfolio companies are Joyo.com (acquired by Amazon.com), SinoCom (0299.HK), Solarfun Power (Nasdaq: SOLF), Spreadtrum Communications (Nasdaq: SPRD), China Sunshine Paper (2002.HK), and VanceInfo (NYSE:VIT), Eyang (0117.HK), etc.As an active investor, Legend Capital provides its portfolio companies extensive business resources and tailored services to assist with business development, company image building, and other critical company building activities on Chinese market so as to add value and maximize returns. Legend Capital is proud and thankful that it has the opportunity to blaze a trail with its innovative practice for China's venture capital industry.
Show more...Investment focus
- Industry: Health Care, Medical, Biotechnology
- Stage:Series B, Series A, Series C
- Geography: China, United States, South Korea
Investor stats
- Total investments: 518
- Round size: Series A $2.9M–$93M; Series B $12M–$100M; Series C $15M–$200M
- Lead/follow: 43% lead, 57% follow
- Last fund: Likely still investing — raised $177M in 2021
Portfolio highlights
- Z.ai — The AI Lab behind GLM models, dedicated to inspiring the development of AGI to benefit humanity. https://t.co/gOw7WpwkJt https://t.co/ot9sGVXU8x
- Huixin Bio — Huixin Bio is a developer of exosome purification products and early cancer detection technology.
- Honghu Future Energy — Honghu Fusion is a commercial nuclear fusion startup developing high-temperature superconducting stellarator technology
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!ANRI is a Japanese venture capital firm that mainly invests in seed and early-stage startups.
Show more...Investment focus
- Industry: Software, Health Care, Information Technology
- Stage:Seed, Series A, Venture - Series Unknown
- Geography: Japan, United States, Indonesia
Investor stats
- Total investments: 315
- Round size: Seed $268k–$9.9M; Series A $967k–$41M; Venture - Series Unknown $616k–$9.1M
- Lead/follow: 24% lead, 76% follow
- Last fund: Likely still investing — raised $102M in 2022
Portfolio highlights
- Any Style — Any Style develops a messaging app from voice actors that regularly sends messages via subscription. It also engages in the planning and production of audio content and the VTuber production business.
- Arrowsmith — Arrowsmith is committed to unlocking the full potential of bacteriophages to revolutionize the treatment of bacterial infectious diseases. Through transformative science, Arrowsmith strive to create a world free from the pain and fear caused by antimicrobial resistance.
- Typewriter Therapeutics — Typewriter Therapeutics, Inc. develops mRNA-based gene therapies using a gene writing, or gene writing, platform for precise insertion of therapeutic genes into the genome. The company builds on transposon-based technologies originating from research by Professor Emeritus Haruhiko Fujiwara at the University of Tokyo. Its programs focus on all‑RNA,nonviral gene writing systems that repurpose natural genetic elements to address severe genetic disorders with limited treatment options. Typewriter Therapeutics conducts research and development across its U.S. and Japan operations and collaborates with investors and partners to advance genetic medicine candidates toward the clinic.
By adopting revolutionary mechanisms, FREES FUND is devoted to change the long-established rules in the venture capital. By leveraging the cutting-edge technologies and resources, FREES FUND aims at investing in great startups and helping them grow into great enterprises that are valuable to our society. We mainly invest in early-stagestartups, and hope to become their first-round institutional investor. Our primary interested areas are broad-sense TMT (Technology, Media, Telecom), B2B and deep technology.
Show more...Investment focus
- Industry: Artificial Intelligence, Health Care, Biotechnology
- Stage:Series A, Seed, Angel
- Geography: China, United States, Singapore
Investor stats
- Total investments: 243
- Round size: Seed $1.4M–$14M; Angel $447k–$10M; Series A $1.6M–$28M
- Lead/follow: 28% lead, 72% follow
- Last fund: May invest from a new fund soon — raised $144M in 2015
Portfolio highlights
- Chuguang 3D — Chuguang 3D is a optical micro-nano 3D sensor technology platform that focuses on research and development, and manufacturing of micro-nano-level optical three-dimensional sensing and measurement and testing instruments.
- Flysound — Flysound is a hearing technology company focused on making advanced AI-powered hearing aids affordable and accessible. Its products combine AI sound processing, Bluetooth connectivity, app-based personalization, and rechargeable convenience. With a focus on innovation, quality, and user-friendly design, Flysound aims to help people hear moreclearly and stay connected to everyday life.
- Yanming Biology — Pyrotech pharmaceuticals is a biotechnology company that focuses om development for drugs for the treatment of inflammation and tumors.
Shenzhen Capital Group Co., Ltd (“SCGC”) is a limited venture capital company established by the Shenzhen Government in 1999. Since its establishment, SCGC has focused on cultivating national industries, shaping national brands, promoting economic transformation, and emerging industries developing. SCGC has registered capital of 5.42 billion RMB,and a total AUM of 338.99 billion RMB. SCGC primarily invests in SMEs, innovative high-tech enterprises, enterprises in emerging industries, and enterprises in start-up period, growth period and in transformation, covering industries supported by national policies, including IT, internet, new media, biopharma, new energy, environmental protection, chemical engineering, new material, high-end equipment manufacturing, consumption goods, modern service, etc. By the end of April 2019, SCGC ranked the first based on the number of portfolio companies and the number of listed portfolio companies: 994 portfolio companies, investments totaling 43.9 billion RMB, 145 of which have been listed in 16 capital markets worldwide.
Show more...Investment focus
- Industry: Manufacturing, Health Care, Software
- Stage:Series A, Series B, Seed
- Geography: China, United States, Japan
Investor stats
- Total investments: 645
- Round size: Seed $1.4M–$29M; Series A $1.6M–$122M; Series B $4.9M–$141M
- Lead/follow: 42% lead, 58% follow
- Last fund: Likely actively investing — fund raised in 2025
Portfolio highlights
- Prosemi — Pusenmei is a precision micro-resistance current sensor developer company committed to delivering professional and diverse precision micro-resistance current detecting resistors and circuit protection solutions.
- Enrikenuo — Enrikenuo is a biotechnology company that focuses on the research and development of new generation CAR-NK technology based cell drugs.
- Waker Biology — Weike Bio is a gene therapy drug development company.
ZhenFund is a seed fund founded by former entrepreneurs to invest in the most promising innovators. New Oriental co-founders Bob Xiaoping Xu and Victor Qiang Wang established ZhenFund in 2011 in collaboration with Sequoia Capital China. ZhenFund now has a network of over 800 portfolio companies, including over 30 unicorns based in China. Webelieve that great businesses start with exceptional founding teams. We are dedicated to helping our entrepreneurs build successful companies by providing them with mentorship and the best resources available. Some of our services include biannual demo days to top Chinese VCs, ZhenHR services, marketing and PR consulting, as well as fundraising. Our strong and large CEO network also facilitates entrepreneurs helping each other, especially via our WeChat platform. ZhenFund has been ranked as the “#1 Early-Stage Investment Firm” for six years. Bob Xiaoping Xu, Founder of ZhenFund, has been named on the Midas List since 2016 and ranked #11 in 2019. Anna Fang, Founding Partner and CEO of ZhenFund, has been named on the Midas List since 2019 and made her 4th appearance as #12, and #1 on Midas Seed List in 2022.
Show more...Investment focus
- Industry: Artificial Intelligence, Software, E-Commerce
- Stage:Seed, Series A, Angel
- Geography: China, United States, Singapore
Investor stats
- Total investments: 751
- Round size: Seed $146k–$14M; Angel $425k–$3M; Series A $873k–$22M
- Lead/follow: 24% lead, 76% follow
- Last fund: Likely still investing — raised $140M in 2022
Portfolio highlights
- Snowplus — SNOWPLUS is an e-cigarette brand that provides users with e-cigarette products through a combination of online and offline sales models. The products are available in 12 different types of flavors. The products use TrueFeel honeycomb ceramic atomization technology and Aeroflow intake. Technology; In addition to reference to the existing food-gradestandards in China, Xuejia has also passed a number of third-party certifications in terms of safety. The core components such as atomizing core and cigarette holder comply with the highest medical safety standards of the FDA and the European Union.
- Futuring Robot — Futuring Robot is a developer of dual-arm home service robots focusing on C-end home scenarios.
- Qisuan Kuang-Chi — Qisuan Kuang-Chi is a pioneering artificial intelligence hardware company focusing on the research, development, and engineering of AI optical computing chips and related system infrastructure. The company utilizes a proprietary all-optical interference technology architecture to bypass physical constraints found in legacy electronic chipsets,aiming to establish computational infrastructure for Artificial General Intelligence (AGI).
Supporting the next generation of entpreneurs in enterprise, healthcare, and consumer with disruptive potential.
Show more...Investment focus
- Industry: Health Care, Medical, Biotechnology
- Stage:Series A, Series B, Venture - Series Unknown
- Geography: China, United States, South Korea
Investor stats
- Total investments: 397
- Round size: Series A $2.9M–$40M; Series B $8.8M–$56M; Venture - Series Unknown $1.5M–$60M
- Lead/follow: 27% lead, 73% follow
- Last fund: Likely still investing — raised $375M in 2021
Portfolio highlights
- Flytech — Flytech specializes in crystal materials and related components for magneto-optical-electrical integrated signal processing.
- Moge Microflow — Moge Microflow is a manufacturer of equipment for microreactors. It provides continuous flow production technologies and equipment for nanomaterials, pharmaceutical intermediates, and fine chemicals, as well as standardized high-end microreactor equipment.
- Bianzhong New Materials — Bianzhong New Materials is a high-tech company that specializes in the research and development of equipment for weaving and shaping three-dimensional preforms of high-strength fiber composite materials.
East Ventures is an early stage venture capital (VC) focused on Southeast Asia, Indonesia & Japan. Success cases include Tokopedia, Traveloka, and Mercari.
Show more...Investment focus
- Industry: Software, Information Technology, E-Commerce
- Stage:Seed, Series A, Venture - Series Unknown
- Geography: Japan, Indonesia, Singapore
Investor stats
- Total investments: 692
- Round size: Seed $250k–$5M; Series A $1.9M–$30M; Venture - Series Unknown $366k–$30M
- Lead/follow: 41% lead, 59% follow
- Last fund: Likely still investing — raised $150M in 2022
Portfolio highlights
- Sisuta — Sisuta is a purpose-driven organization committed to addressing fundamental social issues by seamlessly integrating human insight with advanced technology, creating innovative solutions that empower individuals, strengthen communities, and unlock the full potential of both people and digital tools to drive sustainable social impact.
- BASE — BASE provides web-based services that develop and build e-commerce platforms. The company provides its services across Japan, such as net shop creation, development of shopping applications, development of online payment, and other services.
- Tokoshie — Building infrastructure that inspires everyone to create.
Highlight Capital is an investment firm dedicated to support healthcare companies to generate robust and sustained growth prospect.
Show more...Investment focus
- Industry: Health Care, Medical, Biotechnology
- Stage:Series A, Series B, Seed
- Geography: China, United States, South Korea
Investor stats
- Total investments: 179
- Round size: Seed $10M–$84M; Series A $3.1M–$73M; Series B $7.6M–$70M
- Lead/follow: 35% lead, 65% follow
- Last fund: Likely still investing — raised $563M in 2021
Portfolio highlights
- Genuine Rhythm — Genuine Rhythm is an innovative AI Agent technology developer specializing in bespoke agent creation, advanced algorithm R&D, and rigorous security compliance solutions tailored to diverse enterprise needs.
- Ziwei Technology — Ziwei Technology is a high-tech company making returnable spacecraft.
- Differential Robotics — Differential Robotics is a robotics company providing research, design, and development of aerial robots and intelligent autonomous drones.
Sumitomo Mitsui Banking Corporation (SMBC) and its group companies offer a broad range of financial services centered on banking. They are also engaged in the leasing, securities, credit card, investment, mortgage securitization, venture capital and other credit related businesses. The following lists the activities of SMBC, its subsidiaries andaffiliates in the various business segments.
Show more...Investment focus
- Industry: Information Technology, Software, Health Care
- Stage:Venture - Series Unknown, Series A, Series B
- Geography: Japan, United States, Singapore
Investor stats
- Total investments: 667
- Round size: Series A $1.1M–$32M; Series B $2.3M–$34M; Venture - Series Unknown $800k–$12M
- Lead/follow: 4% lead, 96% follow
- Last fund: May invest from a new fund soon — last raise in 2019
Portfolio highlights
- LQUOM — QWAVE offers cryptography communication technology.
- Etaily — Etaily provides e-commerce and retail solutions in the Philippines, enabling brands with end-to-end services, from store management to fulfillment.
- Link Therapeutics — Link Therapeutics specializes in developing therapeutic methods for targeting autoantibodies and identifying pathogenic autoantibodies.
Catalysing smart monies into Singapore-based, early-stage technology startups.
Show more...Investment focus
- Industry: Biotechnology, Artificial Intelligence, Health Care
- Stage:Seed, Series A, Series B
- Geography: Singapore, United States, Hong Kong
Investor stats
- Total investments: 150
- Round size: Seed $767k–$6.8M; Series A $2.4M–$21M; Series B $5M–$45M
- Lead/follow: 19% lead, 81% follow
Portfolio highlights
- Nexstrom — Nexstrom develops wafer-scale 2D semiconductor technology and manufacturing systems for next-generation computing and AI infrastructure.
- Respiree — They offer platforms that are able to report clinical deterioration and provide recommended interventions with post-monitoring.They work in the health care industry, just like you. We take the time to get to know you, and we always keep your best interests in mind when adding and adjusting products in our catalog.
- Protuoso Biosciences — Protuoso Bio is a pioneering biotechnology company developing Next-Gen MUXBODIES for Complex Diseases. We leverage AI-driven protein engineering and synthetic biology to advance innovative oncology drug research.
Puhua Capital is an equity investment firm that focuses on early and middle project. Puhua Capital provides the required resources and management experience for the invested enterprise, investing funds and more resources and wisdom. Puhua Capital has invested nearly 300 excellent start-ups.
Show more...Investment focus
- Industry: Manufacturing, Health Care, Medical
- Stage:Series A, Series B, Seed
- Geography: China, United Kingdom, United States
Investor stats
- Total investments: 279
- Round size: Seed $2.5M–$30M; Series A $1.5M–$42M; Series B $3M–$103M
- Lead/follow: 33% lead, 67% follow
Portfolio highlights
- Yitang Technology — Yitang Technology is a developer specializing in high-speed and high-precision placement machines. The company is dedicated to the research and development (R&D) of these advanced machines, as well as the industrialization of intelligent production line solutions.
- Ganzhicao Technology — Gancao Doctor is an internet-based Traditional Chinese Medicine (TCM) company that helps clinics modernize their digital management and optimize operations. By using AI-assisted features, it enhances doctors' diagnostic and treatment abilities, delivering valuable benefits to doctors, patients, and clinics.
- Interstellar Lightyear — Interstellar Lightyear Technology is a developer specializing in dexterous robotic hands, focusing on creating intelligent dexterous hands with advanced capabilities for precise manipulation.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!KAITAI CAPITAL, founded in 2009, is a professional investment management organization that mainly engaged in innovative investment, industrial investment, and wealth management business. Fields of investment include biopharma, healthcare services, agriculture tech, consumer business, digital technology and etc.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Pharmaceutical
- Stage:Series A, Seed, Series B
- Geography: China, United States, Singapore
Investor stats
- Total investments: 160
- Round size: Seed $1.4M–$20M; Series A $1.5M–$35M; Series B $10M–$57M
- Lead/follow: 30% lead, 70% follow
Portfolio highlights
- PaXini Tech — All Scenario Application—Haptic Digitization and Tactile Technology
- Yushi Space — Yushi Space is a liquid rocket developer that focuses on the development and manufacture of large-capacity, low-cost and rapidly reusable liquid rockets.
- Guoke Optoelectronics — Guoke Optoelectronics is a national high-tech enterprise integrating comprehensive capabilities in materials processing, chip design, integrated packaging, optoelectronic devices, application algorithms, and system integration. With the mission of "lighting the way for our peers," Guoke Optoelectronics is committed to becoming a globallyleading company in silicon photonics chip technology and overall solutions
Cowin Capital is a private placement equity investment company focusing on investing in a pioneering enterprise on a long-term basis. It has 18 years of experience in capital management, whose capital management scale was among the front rank, which invested more than 300 companies, of which 60 more became public companies, and 150 moresuccessfully exit.The company was successfully listed on NEEQ, with code 832793, as the third listed famous domestic venture capital institution in NEEQ. It is committed to supporting the growth of small and medium enterprises, continue to launch high-quality listed companies in China Capital Market.
Show more...Investment focus
- Industry: Manufacturing, Health Care, Semiconductor
- Stage:Series A, Series B, Seed
- Geography: China, United States, Hong Kong
Investor stats
- Total investments: 366
- Round size: Seed $1.4M–$20M; Series A $2.8M–$51M; Series B $7.2M–$44M
- Lead/follow: 46% lead, 54% follow
- Last fund: May invest from a new fund soon — raised $75M in 2014
Portfolio highlights
- Bytetree — Bytetree is a technology company that focuses on providing the one-stop AI data services for data collection, cleaning, labeling, management, and storage for OEMs and autonomous driving solution providers, covering bicycle intelligence. , vehicle-road coordination, and smart cockpit three scenarios.
- Digital China — Digital China is a robotics company focused on developing humanoid interactive robots that can break traditional boundaries and create emotionally resonated partners.
- Loxun Kuangteng — Longxun Kuangteng injects computing technology, simulation methods, and mathematical algorithms into powerful material simulation tools to help researchers. They develop a software and hardware integration solution to provide customers with a range of services and support. They also provide customers with training, cooperation meetings, and otherservices.
Fast Track Initiative is a venture capital firm with an exclusive focus on life sciences and healthcare services.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Series A, Series B, Seed
- Geography: Japan, United States, United Kingdom
Investor stats
- Total investments: 85
- Round size: Seed $345k–$117M; Series A $3M–$51M; Series B $4.7M–$83M
- Lead/follow: 27% lead, 73% follow
- Last fund: May invest from a new fund soon — raised $124M in 2021
Portfolio highlights
- RegCell — RegCell aims to generate novel therapeutic technologies through augmenting or controlling the immune system and our goal is to save patients who suffer from autoimmune diseases and cancer .
- NovAccel — NovAccel operates as a deep tech company, ensure a stable supply of medical radioisotopes.
- Neusignal Therapeutics — Neusignal Therapeutics is a medical company that develops therapeutic medicines for dementia and psychiatric illnesses.
Legend Star helps entrepreneurs create great businesses through investments, CEO training sessions and an entrepreneurs alliance.Since 2008, Legend Star has incubated and invested in nearly 600 companies and is deeply integrated in the Chinese entrepreneurial ecosystem.Legend Star is the independent early-stage investment arm of LegendHoldings. Legend Holdings is the parent company of Lenovo, Raycom Real Estate, Joyvio Agribusiness and a large range of fast-growing Chinese companies.
Show more...Investment focus
- Industry: Health Care, Medical, Robotics
- Stage:Series A, Seed, Angel
- Geography: China, United States, France
Investor stats
- Total investments: 172
- Round size: Seed $1.5M–$19M; Angel $425k–$7.8M; Series A $1.5M–$52M
- Lead/follow: 23% lead, 77% follow
- Last fund: May invest from a new fund soon — raised $127M in 2018
Portfolio highlights
- CellWall — Cellwall is a desktop robot developer focused on the research, development, upgrade, and marketing of its initial product, CyboPal ONE.
- Ubot Robotics — Ubot Robotics is dedicated to developing leg-and-foot bionic robots and has built a diverse range of bipedal, quadrupedal, hexapodal, and other leg-and-foot bionic robots.
- Active Technology — Active Technology is a pioneering deep tech startup specialized in developing invasive brain computer interface (BCI) technology. The company integrates flexible electrodes, dedicated chips, and advanced decoding algorithms to target motor, visual, and emotional neural pathways.
BioTrack Capital invests in early and growth stage companies within life sciences, healthcare technology, biotechnology and related high-tech sectors, providing capital and investment support for innovation. The firm evaluates scientific and commercial potential of ventures and structures financings aimed at advancing technologies from earlyresearch to market engagement. Its activities include sourcing opportunities, conducting due diligence, and working with founders and management teams to align growth strategies with investor objectives. BioTrack Capital also participates in funding rounds alongside co-investors to support development of novel healthcare and tech solutions. The company engages with portfolio companies through strategic interaction and monitoring of progress toward business milestones.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Seed
- Geography: China, United States, Singapore
Investor stats
- Total investments: 94
- Round size: Seed $15M–$168M; Series A $14M–$45M; Series B $15M–$147M
- Lead/follow: 32% lead, 68% follow
Portfolio highlights
- Taiyi Quantum — Taiyi Quantum is dedicated to encouraging innovation in the distribution and implementation of quantum computing technology, as well as developing sophisticated quantum algorithms and delivering tailored computing solutions for businesses and research institutes.
- Convergen — Convergen develops TrimTAC, a targeted protein degradation platform for treating neurodegenerative diseases and other conditions driven by protein aggregates
- Zhiyue Space Intelligence — Zhiyue Space Intelligence specializes in robotic brain and brain systems.
UntroD Capital is an R&D-based innovative technology that specializes in social implementation.
Show more...Investment focus
- Industry: Manufacturing, Biotechnology, Health Care
- Stage:Seed, Venture - Series Unknown, Series A
- Geography: Japan, Singapore, Austria
Investor stats
- Total investments: 148
- Round size: Seed $316k–$6M; Series A $2.1M–$15M; Venture - Series Unknown $438k–$10M
- Lead/follow: 42% lead, 58% follow
- Last fund: Likely still investing — fund raised in 2024
Portfolio highlights
- JAOPS — JAOPS develops space mission operations software, tools, training, and services for spacecraft control and simulation.
- Eco-Pork — Eco-Pork is a co-creation solution farm that supports farmers' food productivity improvement. It is connecting the pig and technology, pork ( Pork ) new business ecosystems ( Ecosystem By building a), in the pork growing demand around the world, to get the most out of the food supply capacity is finite.
- Teragen Energy — Teragen Energy develops an energy technology platform based on advanced regenerative solid oxide fuel cells that provide both power generation and energy storage in a single system. The company’s systems generate electricity from external fuels such as natural gas or hydrogen without combustion and can operate in reverse to store power as hydrogen.Teragen designs modular systems that can be scaled from megawatt-scale installations for data centers to deployments for microgrids, renewable projects, and utilities. Its technology is intended to help operators manage variable renewable output, ride through outages, and address daily capacity needs using one device. Teragen focuses on applications including AI and cloud data centers, manufacturing and cold storage facilities, remote communities, and electric grid infrastructure. The platform is positioned to replace separate diesel generators and battery systems by combining fuel-flexible generation and low-cost storage in a compact footprint.
Dalton Venture is a fund management company that specializes in early stage investment and industrial mergers and acquisitions in the field of big health.
Show more...Investment focus
- Industry: Health Care, Medical, Biotechnology
- Stage:Seed, Series A, Series B
- Geography: China, India, Canada
Investor stats
- Total investments: 143
- Round size: Seed $512k–$5M; Series A $3M–$17M; Series B $3.2M–$50M
- Lead/follow: 38% lead, 62% follow
Portfolio highlights
- Vibronix — Vibronix innovates for Precision Healthcare with spectroscopic imaging, optical & acoustic sensing, and machine learning.
- PowerMicro — PowerMicro focuses on the cutting-edge interdisciplinary field of “stem cells + engineered scaffolds,” specializing in the application of iPSC technology to advance regenerative medicine, tissue engineering, and innovative therapeutic solutions.
- NewPro — NewPro is in the process of increasing production and establishing regulations for lactoferrin raw materials, with the goal of bringing the product to market as quickly as feasible.
Lenovo Capital and Incubator Group is an accelerator and venture capital firm.
Show more...Investment focus
- Industry: Manufacturing, Artificial Intelligence, Software
- Stage:Series A, Seed, Series B
- Geography: China, Hong Kong, United States
Investor stats
- Total investments: 346
- Round size: Seed $1.4M–$65M; Series A $1.5M–$74M; Series B $8M–$150M
- Lead/follow: 26% lead, 74% follow
- Last fund: May invest from a new fund soon — raised $500M in 2016
Portfolio highlights
- Deepin Technology — Deepin Technology is a company that utilizes artificial intelligence, quantum chemistry, and high-throughput experiment technologies to enhance the efficiency and workflow of chemical material innovation. it offers efficient R&D solutions for chemical materials, aiming to solve lab bottlenecks, promote innovative research, and enhance customervalue.
- SenseTime Medical — SenseTime Medical promotes the development and implementation of its medical big model and provides smart health solutions.
- Jiuwanli Future Technology — Jiuwanli Future Technology is an Integrated circuit design service provider.
Nissay Capital is a venture capital Company specializing in seed, start-up, growth capital, middle stage, and later stage investment.
Show more...Investment focus
- Industry: Health Care, Software, Medical
- Stage:Venture - Series Unknown, Seed, Series A
- Geography: Japan, United States, Ethiopia
Investor stats
- Total investments: 324
- Round size: Seed $455k–$9.6M; Series A $1.2M–$12M; Venture - Series Unknown $899k–$7M
- Lead/follow: 29% lead, 71% follow
- Last fund: May invest from a new fund soon — raised $92M in 2019
Portfolio highlights
- OptQC — OptQC commercializes cutting-edge optical quantum computing technologies developed by the Furusawa-Endo Laboratory. Because optical quantum computers are more scalable than superconducting and other quantum computing implementations, OptQC's optical quantum computers should reach this scale. They also have benefits like faster processing andreduced power consumption, which makes optical quantum computers a possible long-term pinnacle of quantum technology.
- Eight Knot — Eight Knot is a developer of autonomous navigation systems intended for water mobility. They provide autonomous ship maneuvering technology using robotics, enabling customers with water-on-demand transportation using environment-friendly EV robotic boats.
- Zeal Boxing Fitness — Zeal Boxing Fitness combines power of sports with the power of technology to provide a service that allows to enjoy fitness.
Marathon Venture Partners is an international VC fund that focuses on early and growth stage companies in healthcare and Fintech industry.
Show more...Investment focus
- Industry: Health Care, Medical, Biotechnology
- Stage:Series A, Series B, Seed
- Geography: China, United States, Hong Kong
Investor stats
- Total investments: 63
- Round size: Seed $7M–$13M; Series A $1.5M–$29M; Series B $14M–$142M
- Lead/follow: 46% lead, 54% follow
Portfolio highlights
- Fungifuture — Fungifuture is a synthetic biomaterials company specializing in the research and development and production of fungal fiber materials.
- Ruize Health — Ruize Health is a commercial insurance company that focuses on health consumption and commercial insurance.
- Fuxin Technology Innovation — Fuxin Kechuang is a high-tech company that specializes in offering detailed information solutions for the medical and healthcare industries. The business offers creative software solutions and services to a range of healthcare organizations, actively supports the digital transformation of healthcare, and uplifts the medical sector. The company hasgained recognition and has become a partner of big and medium-sized medical institutions and healthcare institutions by relying on its technological research and development power, service capabilities, and ecosystem of medical and health software.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Shanghai Biomedical Industrial Equity focuses on areas that are in line with the development strategy of the biomedical industry.
Show more...Investment focus
- Industry: Health Care, Medical, Biotechnology
- Stage:Series A, Seed, Series B
- Geography: China, United States, Hong Kong
Investor stats
- Total investments: 68
- Round size: Seed $8M–$50M; Series A $14M–$43M; Series B $10M–$159M
- Lead/follow: 60% lead, 40% follow
Portfolio highlights
- BioGeometry — Reshaping the world, one protein at a time
- Surgerii Technology — Beijing Surrey is a technology company founded by an industry elite active in China's medical equipment. Relying on the core technology of the new generation of flexible continuum robotic arm, running through the implementation paradigm of many types of clinical minimally invasive surgery, and harnessing the powerful system design andintegration capabilities, Beijing Shurui is committed to becoming the first independent independent research and development, production and sales in China.
- Beyond Therapeutics — Beyond Therapeutics employs its ExCEED technology to speed the discovery and development of novel medications for unmet therapeutic needs.
CDH Investments is an international alternative asset fund manager with over $27 billion of assets under management. CDH Investments was established in 2002 by the former private equity group of China International Capital Corporation and is managed by an experienced team of senior private equity professionals who have worked together for manyyears focusing all their professional time on investing in China. CDH has consistently delivered superior returns relative to industry peers and is well positioned to continue to generate superior returns due to the team's proven investment experience and expertise investing in China.
Show more...Investment focus
- Industry: Manufacturing, Health Care, Biotechnology
- Stage:Series A, Series B, Series C
- Geography: China, United States, Canada
Investor stats
- Total investments: 329
- Round size: Series A $3M–$100M; Series B $14M–$141M; Series C $30M–$220M
- Lead/follow: 47% lead, 53% follow
- Last fund: May invest from a new fund soon — last raise in 2019
Portfolio highlights
- Synapath — Synapath focuses on using embodied intelligence and robotics technology to create clever systems for making decisions for multi-domain applications that are intelligent.
- Dingxi Zhichuang — Dingxi Zhichuang is an integrated circuit chip developer specializing in the manufacture, design, and services of integrated circuit chips and products, as well as sales and the manufacturing of semiconductor device special equipment.
- Deep Space Matrix Technology — Deep Space Matrix Technology's long-term objective is to benchmark against SpaceX and progressively construct a Chinese equivalent of an integrated air, space, and sea superintelligent system.
Since its founding in 1973, JAFCO has always worked with leading-edge entrepreneurs. The total capital commitments of its investment funds in Japan and overseas have exceeded 1 trillion yen and the number of portfolio IPOs to date has reached over 1,000. In addition to venture investment, JAFCO also carries out buyout investment and commit to thecreations of innovative technologies and services worldwide. As entrepreneurs’ closest partner in bringing their visions to life, JAFCO provides support in areas of HR, marketing/ sales, and back-office operations, in addition to providing financing.
Show more...Investment focus
- Industry: Information Technology, Software, Artificial Intelligence
- Stage:Series A, Series B, Venture - Series Unknown
- Geography: Japan, United States, India
Investor stats
- Total investments: 366
- Round size: Series A $2.1M–$41M; Series B $4.2M–$36M; Venture - Series Unknown $1.4M–$13M
- Lead/follow: 35% lead, 65% follow
- Last fund: May invest from a new fund soon — raised $567M in 2019
Portfolio highlights
- CaTe — CaTe is based in Tokyo. CaTe develops and manufactures a Digital Therapeutic (DTx) for remote cardiac rehabilitation. Their invention allows heart disease patients to safely and successfully complete cardiac rehabilitation utilizing standing exercise in a confined space, such as at home, without the use of ergometers or similar instruments.
- Alxtal — Alxtal is a tech company who optimize the development, design, and manufacturing processes of the manufacturing industry with IT and AI.
- EISHIN — EISHIN is a technology company that specializes in pet tech business, recruitment consulting, website creation, and development services.
Taiyu Investment is an investment firm.
Show more...Investment focus
- Industry: Medical, Health Care, Biotechnology
- Stage:Seed, Series A, Angel
- Geography: China
Investor stats
- Total investments: 49
- Round size: Seed $2.8M–$20M; Angel $434k–$100M; Series A $13M–$29M
- Lead/follow: 18% lead, 82% follow
Portfolio highlights
- Immunocan — Immunocan focuses on the development of fully human antibody animals, artificial chromosome carriers with independent intellectual property rights, focusing on tumor treatment, and developing antibody therapeutic drugs.
- Rhino Medical — Rhino Medical develops advanced technologies with independent intellectual property rights. The founding team has rich experience in R&D, marketing, and clinical. On the basis of benchmarking imported phacoemulsification instruments and vitrectomy instruments
- Infineon Multiomics — Infineon Multiomics is a biotechnology company that provides research and application of space multiomics technology.
Longpan Investment is an investment firm.
Show more...Investment focus
- Industry: Health Care, Medical, Biotechnology
- Stage:Series A, Seed, Series B
- Geography: China, United States, Cayman Islands
Investor stats
- Total investments: 44
- Round size: Seed $14M–$60M; Series A $14M–$32M; Series B $14M–$37M
- Lead/follow: 55% lead, 45% follow
Portfolio highlights
- Jingling Zhikang — Jingling Zhikang is technology company specializing in the intersection of medical rehabilitation, robotics, and embodied artificial intelligence. The company focuses on developing intelligent rehabilitation bionic hands and upper-limb prosthetics.
- Hanyue New Materials — Hanyue Advanced Materials is a high-tech company that specializes in single-use biopharmaceutical solutions.
- Lingtai Krypton Biotechnology — Lingtai Krypton Biotechnology is an innovative corporation that specializes in the development of lncRNA drugs.
UTEC-The University of Tokyo Edge Capital Partners Co., Ltd.. UTEC is a seed/early stage technology focused venture capital firm associated with The University of Tokyo.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Seed, Series A, Series B
- Geography: Japan, United States, India
Investor stats
- Total investments: 212
- Round size: Seed $624k–$12M; Series A $2.3M–$18M; Series B $2.8M–$20M
- Lead/follow: 38% lead, 62% follow
- Last fund: Likely actively investing — fresh fund, raised $326M in 2025
Portfolio highlights
- Mujin — At Mujin, we design automation platforms to enhance any robot, enable advanced capabilities and lower operating costs.
- X Mile — Corporate Site:https://www.xmile.co.jp/ Service Site:https://x-work.jp/
- RegCell — RegCell aims to generate novel therapeutic technologies through augmenting or controlling the immune system and our goal is to save patients who suffer from autoimmune diseases and cancer .
CD Capital is a venture capital firm specialized in life sciences and medical technology. They are currently managing both RMB and USD funds with total size of $600M. CD Capital is operated by a professional team with diversified and profound industry backgrounds. They have made over 40 investments with high growth potential and earned a reputationas a premier venture capital firm with main focus on China healthcare industry. With broad network around China and the world, they have been able to seize the global trend, capture investment opportunities as well as help to define the future for China healthcare industry. Ultimately, they strive to grow best-in-class companies and deliver solid financial return to their investors.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical Device
- Stage:Series A, Series B, Seed
- Geography: China, United States
Investor stats
- Total investments: 73
- Round size: Seed $1.4M–$15M; Series A $1.5M–$32M; Series B $7.6M–$34M
- Lead/follow: 37% lead, 63% follow
Portfolio highlights
- Genlight — Genlight develops innovative treatment solutions for epilepsy and other neurological diseases. Genlight is headquartered in Hangzhou, China.
- Pipi Bear — Pipi Bear is a creator of living robots and health goods, with a focus on those that improve the lives of the elderly.
- CORE Biomedicine — CORE Biomedicine is a private, preclinical-stage biotechnology company that specializes in drug discovery and development for oncology.
Founded in 2009, Cowin Venture is an angel and early-stage investor in TMT and Healthcare. We keep nurturing growth-stage companies graduated from their angel investment portfolio. Cowin’s business network covers China and USA. They have offices in Suzhou, Nanjing, Shanghai, Beijing and Hong Kong.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Series A, Angel, Series B
- Geography: China, United States, Hong Kong
Investor stats
- Total investments: 106
- Round size: Angel $52k–$1.9M; Series A $1.5M–$25M; Series B $3M–$257M
- Lead/follow: 23% lead, 77% follow
Portfolio highlights
- Genta Kyushu Bio — Genta Kyushu Bio is a cutting edge biotechnology company specializing in the development of precision neuro circuit therapies for central nervous system and ophthalmic diseases. The firm leverages its high throughput screening and drug development platforms to advance innovative treatments utilizing chemogenetics, optogenetics, and gene therapies.
- Zhaomo Vacuum — Zhaomo Vacuum is an enterprise integrating R&D, production, commissioning, and service of vacuum chambers.
- StringMotion Future — StringMotion Future focuses on the core technology research and development of tendon-inspired chord-driven robots, creating advanced robotic systems designed to deliver greater flexibility, precision, and efficiency for industrial and intelligent automation applications.
Proxima Ventures focuses in the healthcare industry, supporting outstanding enterprises with innovative technologies or service models that have tremendous potential.They manage multiple funds in RMB and US dollar, covering from seed to growth stages. Their team members with multidisciplinary backgrounds and resourceful networks, have many yearsof remarkable venture capital experience and achievements. They believe that active and effective collaboration with entrepreneurs will make substantial economic returns while bring meaningful improvements in public health.
Show more...Investment focus
- Industry: Medical, Biotechnology, Health Care
- Stage:Seed, Series A
- Geography: China, United States, United Kingdom
Investor stats
- Total investments: 83
- Round size: Seed $2.5M–$30M; Series A $3M–$28M
- Lead/follow: 18% lead, 82% follow
Portfolio highlights
- BCI-Sonics — BCI-Sonics is an innovative medtech company developing non-invasive brain-computer interface solutions using advanced transcranial focused ultrasound (tFUS) technology. The company builds a next-generation therapeutic platform enabling precise neuromodulation to treat central nervous system disorders. BCI-Sonics develops low-intensity focusedultrasound technology that non-invasively stimulates deep brain regions with high precision. They combine ultrasound engineering and neuroscience to interface safely and effectively with the human brain without surgery. The company is creating an AI ultrasound brain-computer interface platform for therapeutic neuromodulation applications.
- Bluesail Surgical — Bluesail Surgical is a surgical device company that specializes in the development of innovative surgical instruments for cardiovascular and cerebrovascular treatments.
- Kingsung Medical Group — Kingsung Medical Group operates under the Mission “Simplify Surgery, Beautiful Life,” with its innovation centered on four core technology platforms at its Tianjin base: Mechanical Design, Polymer Materials, Biodegradable Magnesium Alloys, and Collagen Biomaterials. These platforms have enabled the development of pioneering medical devices,including microvascular anastomosis devices and neural tube. In particular, the Group’s biodegradable magnesium alloy technology is spearheading the advancement of next-generation orthopedic implants. Kingsung’s technological capabilities are evidenced by a portfolio of over 190 patents and its recognition as a National Key Enterprise. The Group also actively contributes to the industry as a standing council member of the Microsurgery Branch of the China Association of Medical Devices Industry and a member of the Chinese Society for Biomaterials.
Sinovation Ventures is a full-service venture capital firm that actively invests in the Chinese technology market.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Health Care
- Stage:Series A, Seed, Series B
- Geography: China, United States, Hong Kong
Investor stats
- Total investments: 377
- Round size: Seed $882k–$14M; Series A $1.5M–$30M; Series B $3M–$74M
- Lead/follow: 31% lead, 69% follow
- Last fund: Likely still investing — raised $203M in 2022
Portfolio highlights
- Hemu Intelligent — Hemu Intelligent is an early-stage Industrial AI startup focused on mold physical AI, manufacturing semantic computing, and industrial application. By leveraging deep learning on mechanical drawings and digitizing the experiential workflows of master technicians, the company builds an "AI Craft Brain".
- Jiangxian Technology — Jiangxian Technology is a company focused on embodied intelligence, a field that integrates artificial intelligence with physical systems such as robots and smart devices, enabling machines to perceive, learn from, and interact with the real world in a more human-like and adaptive manner across applications like automation, healthcare, and advancedmanufacturing.
- Ruilian Intelligent Computing — Ruilian Zhisuan is an AI computing infrastructure innovator that provides integrated hardware software solutions. Modeled after Google's Jupiter optoelectronic architecture, it features full stack OCS scheduling to replace traditional electronic switches with optical routing. This core technology drastically minimizes network latency andsystem power consumption for advanced AI calculation networks.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Sherpa Venture Capital is an investment firm that focuses on the investment and cultivation of the Pharmaceutical and Biotech industry. It also specializes in the investment and management of sector leaders and innovators within the Pharma, GeneTech, MedTech, Medical services, and various sub-sectors, where they have established robust portfoliosources, lasting value-adding cooperations and relationships, as well as mature all-cycle services with key resources. It was founded in 2018 and is headquartered in Beijing, China.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: China, United States, Kenya
Investor stats
- Total investments: 103
- Round size: Series A $7.2M–$50M; Series B $15M–$100M; Series C $21M–$128M
- Lead/follow: 28% lead, 72% follow
- Last fund: May invest from a new fund soon — last raise in 2021
Portfolio highlights
- AusperBio — AusperBio is a Phase II clinical-stage biopharmaceutical company dedicated to transforming hepatitis B treatment for a cure and advancing oligonucleotide therapeutics. Leveraging their innovative and proprietary Med-Oligo™ ASO platform with effective targeted delivery technologies, AusperBio strives to unleash the power of ASO therapeutics to treata wide range of diseases, including viral infections, metabolic conditions, genetic disorders, and immune diseases.
- Shenfu Jianxing — Shenfu Jianxing is a brain-computer interface developer. It focuses on minimally invasive implanted brain-spinal interface technology, with "minimally invasive + low latency + high integration" as its core, to build implantable brain-spinal neural stimulation systems.
- Archimedes Vascular — Archimedes Vascular operates as a medical device company, that treat patients with severe hypertension.
Addor Capital offers investment services by financing early stage ventures and holding securities of other companies.
Show more...Investment focus
- Industry: Manufacturing, Semiconductor, Electronics
- Stage:Series A, Series B, Venture - Series Unknown
- Geography: China, Hong Kong, United States
Investor stats
- Total investments: 363
- Round size: Series A $1.6M–$30M; Series B $12M–$145M; Venture - Series Unknown $1.4M–$101M
- Lead/follow: 50% lead, 50% follow
- Last fund: May invest from a new fund soon — raised $241M in 2021
Portfolio highlights
- Ibeki — Ibeki provides tiny photoelectric displacement sensors and servo control systems. eBridge uses the high precision and miniaturization of its precision motion drive technology to provide customers with a more complete technology portfolio, and has successfully transformed its core technology into a number of military and civilian products,particularly in aerospace, medical equipment, and intelligent control.
- Deep Blue Aerospace — Deep Blue Aerospace is a commercial carrier rocket developer.
- Ruimeng Semiconductor — Ruimeng Semiconductor is a provider of intelligent human-machine interface processor chips and solutions.
Huagai Capital is a private equity investment firm that invests in start-up or growth companies in the areas of healthcare, TMT, and culture.
Show more...Investment focus
- Industry: Health Care, Medical, Biotechnology
- Stage:Series A, Series B, Angel
- Geography: China, United States, Hong Kong
Investor stats
- Total investments: 153
- Round size: Angel $425k–$15M; Series A $1.5M–$73M; Series B $8.5M–$90M
- Lead/follow: 41% lead, 59% follow
- Last fund: May invest from a new fund soon — raised $430M in 2018
Portfolio highlights
- SeaArt — SeaArt AI is an all-in-one AI creativity community for art, videos, audio, and AI chats, where creators collaborate, spark inspiration, and grow together.
- Zhiran Medical — Zhiran Medical is a medical technology company specializing in the precise detection and treatment of neurological disorders using high-throughput, flexible brain-computer interface technology.
- GigaAI — Excellent Vision is a spatial intelligence company focused to transforming video creation into a 4D world model, enabling AI big models to grasp, generate, and reason about 4D space.
Shenzhen Green Pine Capital Partners Co. Ltd. (“GPCP”) was established in 2007, with the investment team assembled in 2000. GPCP is one of the most time-honored Chinese VC companies that boast experience in areas such as biotech, new materials, new resources and AI, etc. Currently, GPCP manages assets over 15 billion RMB through 21 special fundsand have invested 7 billion RMB into 388 enterprises among which 14 are listed on NEEQ and 48 of them are either listed or acquired by listed companies, including BGI(300676.SZ), Aurora(600666.SH), Nationz Tech(300077.SZ), Foresee(002530.SZ), Qudian(NASDAQ:QD), etc. GPCP invested in the angel round of BGI (Beijing Genomics Institute), Royole, Kuang-Chi, Appotronics, BMF, C-one, Arrayed Materials and other star enterprises.GPCP is based in Shenzhen, with branches in Beijing, Shanghai and Guangzhou. GPCP also runs two GPI incubators and an incubator for overseas Chinese scientists who start businesses in China.
Show more...Investment focus
- Industry: Artificial Intelligence, Biotechnology, Manufacturing
- Stage:Series A, Angel, Series B
- Geography: China, United States, Canada
Investor stats
- Total investments: 244
- Round size: Angel $425k–$3.1M; Series A $1.5M–$60M; Series B $3M–$150M
- Lead/follow: 32% lead, 68% follow
- Last fund: Likely actively investing — fresh fund, raised $42M in 2025
Portfolio highlights
- Enrikenuo — Enrikenuo is a biotechnology company that focuses on the research and development of new generation CAR-NK technology based cell drugs.
- Sungen Biomedical — Sungen Biomedical is an innovative antibody drug R&D enterprise. It has established international standard technology platforms and original biological macromolecular R&D pipelines. Their focus includes therapeutic drugs for cardiovascular and cerebrovascular diseases, tumors, and more.
- Chiplight Technology — Chipligh Technology develops optical interconnect and silicon photonics solutions for AI computing clusters.
Mizuho is the venture capital firm affiliated to Mizuho Bank, the second-largest Japanese bank in terms of assets. The firm has headquarters in Tokyo.The firm has ¥49.6 billion JPY under management, focusing on information technology and biotechnology investments. Over 600 Mizuho companies have gone public. According to Nikkei, Mizuho is thefifth-largest venture capital firm in Japan.Mizuho Capital was formed in 2002 by the merger of Fujigin Capital, Tokyo Venture Capital and IBJ Investment. Three firms were subsidiaries of Fuji Bank, Dai-Ichi Kangyo Bank and the Industrial Bank of Japan respectively.
Show more...Investment focus
- Industry: Information Technology, Software, Artificial Intelligence
- Stage:Series A, Venture - Series Unknown, Series B
- Geography: Japan, United States, Singapore
Investor stats
- Total investments: 545
- Round size: Series A $1.4M–$32M; Series B $2.4M–$47M; Venture - Series Unknown $661k–$10M
- Lead/follow: 5% lead, 95% follow
- Last fund: May invest from a new fund soon — raised $92M in 2020
Portfolio highlights
- CaTe — CaTe is based in Tokyo. CaTe develops and manufactures a Digital Therapeutic (DTx) for remote cardiac rehabilitation. Their invention allows heart disease patients to safely and successfully complete cardiac rehabilitation utilizing standing exercise in a confined space, such as at home, without the use of ergometers or similar instruments.
- AIONA — AIONA uses AI to produce high-quality products and provides everyone with access to knowledge.
- Yoom — Yoom is a consulting company that offers system development services on AI, IoT, data solutions, and cloud integration.
Founded in 2005, Hillhouse is a leading global investment management firm, active across public equity, private equity, real estate and private credit. The firm invests over a long-term horizon and partners with exceptional entrepreneurs to deliver sustainable value creation for quality companies.Hillhouse is a full life-cycle private equityfirm, investing for the long term across opportunities in the healthcare, business services, consumer, and industrials sectors. The firm manages capital on behalf of global institutions such as non-profit foundations, endowments, and pensions.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series B, Series A, Series C
- Geography: China, United States, Singapore
Investor stats
- Total investments: 455
- Round size: Series A $2.9M–$153M; Series B $12M–$219M; Series C $16M–$300M
- Lead/follow: 44% lead, 56% follow
- Last fund: Likely still investing — raised $1.4B in 2023
Portfolio highlights
- KMC Solutions — Build global teams in the Philippines and Colombia with KMC's Employer of Record, recruitment, HR, payroll, and flexible office solutions.
- LifeLabs Design — LifeLabs patented warming & cooling technology allows for comfort across extreme temperatures. Explore our dedication to producing sustainable & eco-friendly fabrics.
- DayOne — GDS International portfolio currently comprises approximately 480 MW of data center capacity in service and under construction and an additional 590 MW held for future development across strategic locations in Hong Kong, Singapore, Malaysia (Johor), Indonesia (Batam), and Japan (Tokyo).
Gaorong Capital is a venture capital firm that focuses on early and growth stage investments in TMT, including AI and frontier technologies.
Show more...Investment focus
- Industry: Artificial Intelligence, Information Technology, Software
- Stage:Series A, Series B, Seed
- Geography: China, United States, Singapore
Investor stats
- Total investments: 370
- Round size: Seed $2.8M–$100M; Series A $1.6M–$75M; Series B $14M–$110M
- Lead/follow: 29% lead, 71% follow
- Last fund: Likely still investing — raised $185M in 2022
Portfolio highlights
- Anew Labs — Anew Labs is an AI drug discovery company that combines generative models with experimental science.
- Cascade — Cascade produces novel medications that target nuclear receptors for treating metabolic disorders and inflammation.
- Sequence Technology — Sequence Technology emphasizes in the production of polymer materials used in the semiconductor manufacturing process.
Oriza Holdings is a Chinese management fund that covers equity, debt financing, and investment since 2007.
Show more...Investment focus
- Industry: Manufacturing, Health Care, Biotechnology
- Stage:Series A, Series B, Series C
- Geography: China, United States, Canada
Investor stats
- Total investments: 220
- Round size: Series A $1.5M–$55M; Series B $10M–$100M; Series C $14M–$200M
- Lead/follow: 27% lead, 73% follow
Portfolio highlights
- ChipSine — ChipSine is an Integrated Circuit (IC) design company that focuses on the research and development of automotive-grade electronic control chips.
- Empower — Empower is an enterprise platform focused on intelligent laser manufacturing that makes lasers smart.
- Neowise — XinjingZhiyuan is an immune cell therapy company focusing on solid tumors.
Shunwei Capital is a venture capital fund that focuses on early to mid-stage investments in local internet industry. It specializes in incubation, startups, early to mid-stage, and growth capital investments. It seeks to invest in the technology, media, telecommunications, high technology, new media, games, internet finance, and rural area internetsectors. Their investors include sovereign wealth funds, fund of funds, university endowment funds, and family offices.
Show more...Investment focus
- Industry: Manufacturing, Software, Artificial Intelligence
- Stage:Series A, Series B, Seed
- Geography: China, United States, India
Investor stats
- Total investments: 616
- Round size: Seed $1M–$74M; Series A $1.5M–$41M; Series B $8.2M–$55M
- Lead/follow: 32% lead, 68% follow
- Last fund: May invest from a new fund soon — raised $1.2B in 2018
Portfolio highlights
- Z.ai — The AI Lab behind GLM models, dedicated to inspiring the development of AGI to benefit humanity. https://t.co/gOw7WpwkJt https://t.co/ot9sGVXU8x
- Sleptay — Sleptay is an innovative biopharmaceutical company, developing next-generation therapies for central nervous system diseases.
- Baiyue Interlink — Baiyue Interlink is a commercial aerospace company capable of reusable Level 1 and Level 2 space transportation.
Nippon Venture Capital ("NVCC"), established in 1996 as one of the few largest Japanese independent venture capital firms, is destined to undertake the unprecedented task of providing full-range venture capital services in cooperation with major Japanese business leaders and leading companies, which have supported and nurtured various newbusinesses on their own, as well as proactively developing new venture enterprises.
Show more...Investment focus
- Industry: Software, Health Care, Medical
- Stage:Venture - Series Unknown, Series A, Series B
- Geography: Japan, United States, Indonesia
Investor stats
- Total investments: 203
- Round size: Series A $1.5M–$45M; Series B $3.3M–$33M; Venture - Series Unknown $457k–$12M
- Lead/follow: 17% lead, 83% follow
- Last fund: Likely still investing — raised $15M in 2023
Portfolio highlights
- KUZEN — KUZEN provides enterprise-grade chatbot technologies, especially the bot framework and NLP, via a visual UI without coding. The company is utilizing technology to develop a system that broadens the scope of dialogue. They use technology to provide their customers with next-generation standard procedures that broaden the possibilities ofconversation, resulting in unprecedented business practices.
- AOI Biosciences — AOI Biosciences is a biotechnology company that creates testing and drug discovery businesses.
- Neusignal Therapeutics — Neusignal Therapeutics is a medical company that develops therapeutic medicines for dementia and psychiatric illnesses.
FAQ
Is Shizune data fresh/accurate?
Shizune has monitored hundreds of funding sources since 2020.
Our investor database is updated every day, so investor data is always fresh.
All metrics are calculated from confirmed public rounds, so the data is accurate.
Can I download investor list?
To download the Health Care VC Funds in Asia investor list, create a Shizune account. This investor list will be added to your saved investors and available for download in the export section.
You can also enrich the investor list with investor emails, phones, LinkedIns, and other contact data.
Can I access investor database?
To access all 48,091 VC funds investing in Asia Health Care startups and 48,091+ more investors, create a Shizune account.
Shizune has a database of 48,091 investors. Our investor database is fresh and updated daily.
The Shizune investor database has information on investor investment focus, investor contact data, and full investor portfolio since 2020.
You can enrich with email and download the data.
Does Shizune have investor emails and contacts?
Shizune enriches investors with contact data that includes: email, phones, LinkedIn, socials, website, and others.
To guarantee the highest discovery rate, we search across 20+ contact search tools.
To maximize delivery rate and reduce bounce rate, we validate emails.
You can enrich your investor list with Shizune. Download it too.
What is Shizune?
Shizune is a 48,091 investor database updated daily.
With Shizune you can:
- browse the database
- use smart matching
- enrich with emails
- download
All you need to find investors for your startup.
Who is Shizune for?
Shizune is built for startup founders by startup founders.
If you are looking for funding for your startup, try the Shizune database — we have investors for every stage, industry, and country.
Is Shizune free?
Shizune is free forever. You can search and browse investors for free.
Email search and export are paid features.
For full info, visit our pricing.
Who built Shizune?
Shizune is built by founders with the goal of helping all founders raise funding no matter where they are.
Contact 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!